No Data
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $62
Barclays Maintains MoonLake Immunotherapeutics(MLTX.US) With Hold Rating, Maintains Target Price $55
MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $55 to $100
Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Avidity Biosciences (RNA) and MoonLake Immunotherapeutics (MLTX)
Strategic Initiatives and Financial Stability Propel MoonLake Immunotherapeutics Towards Promising Market Position
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
